First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

埃罗替尼 医学 肿瘤科 内科学 表皮生长因子受体 肺癌 盐酸厄洛替尼 临床终点 T790米 无进展生存期 癌症 进行性疾病 临床试验 化疗 吉非替尼
作者
Keunchil Park,Chong‐Jen Yu,Sang-We Kim,Meng-Chih Lin,Virote Sriuranpong,Chun-Ming Tsai,Jong-Seok Lee,Jin Hyoung Kang,K.C. Chan,Pablo Ernesto Pérez,Peter Button,Myung‐Ju Ahn,Tony Mok
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:2 (3): 305-305 被引量:208
标识
DOI:10.1001/jamaoncol.2015.4921
摘要

Continuing molecularly targeted treatment beyond disease progression in non-small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses, highlighting the challenge to identify whether progression is the optimal time to switch treatment.To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy.ASPIRATION (Asian Pacific trial of Tarceva as first-line in EGFR mutation) was a phase 2, open-label, single-arm study conducted from 2011 to 2012 in 23 centers in Hong Kong, Korea, Taiwan, and Thailand of adults with stage IV, EGFR mutation-positive NSCLC, with ECOG performance status 0 to 2.Patients received erlotinib 150 mg/d orally until disease progression, after which erlotinib therapy could be continued at patient and/or investigator discretion.The primary end point was progression-free survival (PFS1; time to Response Evaluation Criteria in Solid Tumours 1.1 progression or death). Secondary end points included PFS2 (time to off-erlotinib progression if erlotinib therapy was extended beyond progression at patient and/or investigator discretion), objective response rate, disease control rate, overall survival, and safety. The use of plasma-based assessment of EGFR mutations was also investigated.Of 359 patients screened, 208 were enrolled. Median follow-up was 11.3 (95% CI, 10.9-13.0) months. Of the 207 intent-to-treat patients (62.3% female; median age, 60.8 [range, 28-89] y), 176 had a PFS1 event (171 progression and 5 deaths); of these, 78 discontinued and 93 continued erlotinib therapy following progression. Median PFS1 was 10.8 (95% CI, 9.2-11.1) months. Median PFS1 and PFS2 in the 93 continuing patients was 11.0 (95% CI, 9.2-11.1) and 14.1 (95% CI, 12.2-15.9) months, respectively. Median PFS1 and PFS2 was 11.0 (95% CI, 9.3-12.0) and 14.9 (95% CI, 12.2-17.2) months in patients with exon 19 deletions or L585R mutations. Overall response rate was 66.2%; disease control rate was 82.6%. Median overall survival was 31.0 months (95% CI, 27.3 months to not reached). In the safety population (n = 207) serious adverse events were reported in 27.1%, with events of at least grade 3 experienced by 50.2%. Sensitivity and specificity of plasma-based EGFR mutation analysis was 77% and 92%, respectively.ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation-positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients.clinicaltrials.gov Identifier: NCT01310036.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
s615应助自觉冰之采纳,获得30
1秒前
1秒前
2秒前
2秒前
田様应助独一无二采纳,获得10
2秒前
3秒前
3秒前
花开富贵完成签到,获得积分10
3秒前
上官若男应助CO2采纳,获得10
4秒前
Denvir完成签到 ,获得积分10
4秒前
4秒前
失眠的水云完成签到,获得积分10
5秒前
11完成签到,获得积分10
5秒前
如意雅山发布了新的文献求助10
5秒前
5秒前
April完成签到 ,获得积分10
5秒前
7秒前
ikang发布了新的文献求助10
7秒前
bkagyin应助Tim采纳,获得10
7秒前
bqin发布了新的文献求助10
8秒前
神说完成签到,获得积分0
9秒前
建成发布了新的文献求助10
9秒前
9秒前
乐观小之应助如意雅山采纳,获得10
9秒前
鲤鱼问雁完成签到,获得积分10
10秒前
ricky完成签到,获得积分10
10秒前
顾矜应助boom采纳,获得10
11秒前
11秒前
struggling2026完成签到 ,获得积分10
12秒前
云云发布了新的文献求助30
12秒前
害怕导师的小可怜完成签到,获得积分10
12秒前
bqin完成签到,获得积分10
14秒前
14秒前
生活是意见完成签到,获得积分10
14秒前
昂口3发布了新的文献求助10
14秒前
脑洞疼应助霸气忆灵采纳,获得10
16秒前
脸脸发布了新的文献求助10
16秒前
zym123发布了新的文献求助20
16秒前
如意雅山完成签到,获得积分10
16秒前
高分求助中
Lorenz Luthi - The Regional Cold Wars in Europe, East Asia, and the Middle East Crucial Periods and Turning Points 1000
Tracking and Data Fusion: A Handbook of Algorithms 1000
Models of Teaching(The 10th Edition,第10版!)《教学模式》(第10版!) 800
Full waveform acoustic data processing 500
Bounded Meaning: The Dynamics of Interpretation 400
Operative Techniques in Pediatric Orthopaedic Surgery 400
More Activities for Teaching Positive Psychology A Guide for Instructors 330
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2881969
求助须知:如何正确求助?哪些是违规求助? 2498658
关于积分的说明 6763131
捐赠科研通 2177222
什么是DOI,文献DOI怎么找? 1157135
版权声明 586290
科研通“疑难数据库(出版商)”最低求助积分说明 567925